ライフサイエンスコーパス: pharmacist

1 follow-up visits for 6 months (all by their pharmacist).

2 tioners (ie, physicians, allergists, nurses, pharmacists).

3 research nurse, a physician, and a clinical pharmacist.

4 identity to the masked staff by an unmasked pharmacist.

5 personnel remained blinded except the local pharmacist.

6 greater; blinding was known only to the site pharmacist.

7 a drug accountability auditor, and the site pharmacist.

8 However, PEFR data were not provided to the pharmacist.

9 ed random numbers were provided by the study pharmacist.

10 e treatment assignment, except for the study pharmacist.

11 elayed to primary teams and tracked by local pharmacists.

12 nurses, 30 school first aiders, 30 community pharmacists.

13 d skin and soft tissue infections with local pharmacists.

14 purchasing patterns and alert physicians and pharmacists.

15 professors and its repeated use in training pharmacists.

16 itals should consider employing clinical ICU pharmacists.

17 rding to the absence or presence of clinical pharmacists.

18 comprising infectious disease physicians and pharmacists.

19 y American Society of Hypertension-certified pharmacists.

20 dermatologists, clinical immunologists, and pharmacists.

21 d skin and soft tissue infections with local pharmacists.

22 ced practice providers (10.5%; n = 263), and pharmacists (2.1%; n = 52), reflecting a 1.6% response r

23 -8.12 mm Hg (-10.23 to -6.01, I(2)=57%) for pharmacists, -4.67 mm Hg (-7.09 to -2.24, I(2)=0%) for d

24 s after initiation of the program, 24 of 302 pharmacists (7.9%), 35 of 302 prescribers (11.6%), and 5

25 y have prevented 93% and ward-based clinical pharmacists 94% of potential ADEs.

26 mple opportunities to implement the program, pharmacists accessed patient-specific data only about ha

27 A position paper outlining critical care pharmacist activities was last published in 2000.

28 who received care within an integrated nurse/pharmacist adherence support program.

29 In the control group, pharmacists advised women to attend their usual contrace

30 ith emergency contraception from a community pharmacist, along with an invitation to a sexual and rep

31 The intervention involved 1 pharmacist and a single study site that served a large,

32 ractice that characterizes the critical care pharmacist and critical care pharmacy services.

33 ication Therapy Management review from their pharmacist and CVD risk assessment and education.

34 The pharmacist and physician adjusted medication to manage e

35 nsion information, and usual care from their pharmacist and physician.

36 nt education; (3) collaborative care between pharmacist and primary care provider/cardiologist; and (

37 The focus for the pharmacist and the ICU team must be on the optimization

38 delineate the activities of a critical care pharmacist and the scope of pharmacy services within the

39 care interventions recommended by a clinical pharmacist and to specifically examine cost savings (or

40 y American Society of Hypertension-certified pharmacists and demonstrated efficacy in a 6-month clust

41 Interventions led by pharmacists and nurses, which include patient education,

42 pediatric and adult specialists, dieticians, pharmacists and paramedics.

43 ription through its evaluation by practicing pharmacists and pharmacy professors and its repeated use

44 An online survey was conducted among 201 pharmacists and pharmacy technicians from an existing pa

45 ip was delivered using in-person coaching by pharmacists and physicians three to five times weekly, a

46 dialysis establish dosing guidelines for all pharmacists and physicians to follow to provide consiste

47 tegrated care models between community-based pharmacists and primary medical providers may identify a

48 Patients and all study personnel, except for pharmacists and statisticians, were masked to treatment

49 ere reviewed for references to critical care pharmacists and their role on the multiprofessional crit

50 er study site staff (except for the unmasked pharmacist), and patients were masked to pembrolizumab v

51 isted of a primary care general internist, a pharmacist, and a nurse or other certified diabetes educ

52 oenterologists, medical oncologists, nurses, pharmacist, and a surgeon.

53 onent intervention, often led by an oncology pharmacist, and also included patient education and regu

54 en the treating elder care physician and the pharmacist, and implementation of medication changes.

55 ed a nurse depression care manager, clinical pharmacist, and psychiatrist.

56 kers, case managers, financial coordinators, pharmacists, and clinicians.

57 cal microbiologists, infectious disease (ID) pharmacists, and infectious disease physicians represent

58 d medication education, regular follow-up by pharmacists, and medications dispensed in time-specific

59 participants, care teams, outcome assessors, pharmacists, and members of the trial management group w

60 of no greater than 1:2, adding critical care pharmacists, and providing dedicated respiratory therapi

61 ors, registered dietitians, epidemiologists, pharmacists, and public health experts, continuously sea

62 ors, registered dietitians, epidemiologists, pharmacists, and public health experts.

63 ists, pharmaceutical scientists, physicians, pharmacists, and regulatory specialists to explore strat

64 e practitioner, physician assistant, nurses, pharmacists, and student members of the Society of Criti

65 (3) a shared review by the physician and the pharmacist; and (4) a daily, rounding-based, in-person a

66 ced-practice providers and medical trainees; pharmacists; and translational and basic science researc

67 e intervention arm will visit with the study pharmacist approximately 1 week post-hospital discharge.

68 In the UK, doctors, dentists, coroners, and pharmacists are allowed to report through the yellow car

69 Critical care pharmacists are essential members of the multiprofession

70 Pharmacists are key partners in antimicrobial stewardshi

71 Critical care pharmacists are recognized as essential members of the c

72 A collaboration of physicians and pharmacists are working closely with Epic to provide a m

73 ized skills characterizing the critical care pharmacist as clinician, educator, researcher, and manag

74 d skills that characterize the critical care pharmacist as clinician, educator, researcher, and manag

75 Based on previous studies, pharmacists as part of the interdisciplinary team could

76 The pharmacist assigned treatment on the basis of a randomis

77 Pharmacist-assisted medication reconciliation, inpatient

78 he prospective cohort were identified by the pharmacist at the patient's first clinic visit (1.1 erro

79 Pharmacists at a UK teaching hospital prospectively iden

80 Specific pharmacist-based activities were associated with greater

81 ccination was ascertained from physician and pharmacist billing claims.

82 ion status was determined from physician and pharmacist billing claims.

83 Group assignment was not masked from study pharmacists, but allocation was concealed from participa

84 were faxed to the antimicrobial stewardship pharmacist by noon each day in order to evaluate empiric

85 an off-site team: a nurse care manager and a pharmacist by telephone, and a psychologist and a psychi

86 A clinical pharmacist called patients 2 to 4 days after discharge t

87 opriate use of antibiotics and what role the pharmacist can play in ensuring the optimal use of infec

88 Physicians and pharmacists can play an important role in providing syri

89 Pharmacists can substitute biosimilars for reference bio

90 vascular care, including the use of clinical pharmacists, can efficiently deliver high-quality care.

91 Diastolic BP was decreased only in the pharmacist care group compared with both the usual care

92 ved home BP monitoring and Web training plus pharmacist care had a greater net reduction in systolic

93 Pharmacist care management delivered through secure pati

94 ng and secure patient Web site training plus pharmacist care management delivered through Web communi

95 Adding Web-based pharmacist care to home BP monitoring and Web training s

96 atients were randomized to usual care (usual pharmacist care with no specific intervention) or interv

97 to home BP monitoring and Web training plus pharmacist care.

98 Home BP telemonitoring and pharmacist case management achieved better BP control co

99 including nurses, case managers, physicians, pharmacists, case workers, dietitians, physical therapis

100 fectious disease specialists (physicians and pharmacists), clinical microbiologists, and infection co

101 of this study was to evaluate if a physician/pharmacist collaborative model would be implemented as d

102 (ICU) has been shown to prevent errors, and pharmacist consultation has reduced drug costs.

103 ssisted medication reconciliation, inpatient pharmacist counseling, low-literacy adherence aids, and

104 ntly reduced by a health-literacy-sensitive, pharmacist-delivered intervention.

105 zed trial of CVD risk reduction by community pharmacists, demonstrating a significant reduction in ri

106 ian assistants, nurses, nurse practitioners, pharmacists, dentists, dental hygienists, occupational t

107 The sensitivity and specificity of clinical pharmacists diagnosing AF using pulse palpation was 76.9

108 es, nurse prescribers, Physician Assistants, pharmacists, dieticians, and physical or occupational th

109 e 24-wk study period, the pediatric clinical pharmacist documented all interventions that occurred du

110 informatics into the management of SAB via a pharmacist-driven initiative.

111 An automated, pharmacist-driven intervention for the management of pat

112 fied included appropriate patient selection, pharmacist-driven patient education, and pharmacist-led

113 versus MALDI-TOF MS combined with real-time, pharmacist-driven, antimicrobial stewardship (AMS) inter

114 We implemented a pharmacist-driven, prospective audit and feedback strate

115 ne way to ensure enough doctors, nurses, and pharmacists during the COVID-19 pandemic: Enable graduat

116 nt care, primarily relating to critical care pharmacist duties and pharmacy services.

117 nt care, primarily relating to critical care pharmacist duties and pharmacy services.

118 ansplant coordinator, psychologist, clinical pharmacist], electronic reminder and support systems (eg

119 Nurses, physicians, and pharmacists endorsed its enhancement of interdisciplinar

120 The institution of a daily pharmacist-enforced intervention directed at improving s

121 computer alert appeared on the screen to the pharmacist entering the order, who could then consult th

122 In the prospective group, a pharmacist evaluated all mechanically ventilated patient

123 ension in the 24 hours prior to the clinical pharmacists' evaluation.

124 rovided information and met with a community pharmacist for scheduled visits at baseline, 3, 6, 9, an

125 Forty-seven pharmacists from 41 eligible sites participated in the q

126 Consensus opinion of critical care pharmacists from institutions of various sizes providing

127 es were defined as having at least a partial pharmacist full-time equivalent specifically devoted to

128 reaction assay, with physician education and pharmacist guidance, did not significantly reduce excess

129 ICUs that did not have clinical pharmacists had greater total Medicare billings of 12% (

130 Only the database administrator and research pharmacists had knowledge of treatment assignment.

131 The statistician and pharmacists had no role in assessing the participants or

132 Clinical pharmacists have a substantial effect in a wide variety

133 Over the past 20 yrs, pharmacists have successfully integrated their services

134 physicians, infectious disease specialists, pharmacists, hospital administrators, and government ent

135 ludes an infectious disease specialist and a pharmacist in addition to the burn surgeon is highly rec

136 t centers do not have a dedicated transplant pharmacist in outpatient care.

137 ations address the role of the critical care pharmacist in patient and medication safety, clinical qu

138 e average time spent per day by the clinical pharmacist in the pediatric intensive care unit was 0.73

139 spiratory therapists in 26 of 43 (60.5%) and pharmacists in 23 of 43 (53.5%).

140 Pharmacists in both control groups had a training sessio

141 This essay describes the role of community pharmacists in implementing the system and distributing

142 nsmission among drug-using patients and that pharmacists in most states have a clear or reasonable le

143 Background: Increased involvement of pharmacists in patient care may increase access to healt

144 The involvement of clinical pharmacists in the care of critically ill Medicare patie

145 to support the potential role of nurses and pharmacists in the effective management of chronic pain.

146 atient characteristics, presence of clinical pharmacists in the ICU (odds ratio [OR], 0.67; 95% CI, 0

147 tation of protocols and presence of clinical pharmacists in the ICU, and close collaboration between

148 We suggest broader adoption for the role of pharmacists in the provision of penicillin skin testing.

149 igators (two physicians, two nurses, and one pharmacist) in adult ICU patient encounters (n = 192).

150 makers should consider an expanded role for pharmacists, including prescribing, to address the burde

151 alert sent to the covering provider and unit pharmacist indicating new acute kidney injury) or usual

152 re characterized as collectivist (input from pharmacists, infectious disease, and medical microbiolog

153 A pharmacist intervention for outpatients with heart failu

154 is study was to document the impact of daily pharmacist interventions on clinical outcomes of intensi

155 d by 5.3% (CI, 2.6% to 7.6%; P < 0.001), and pharmacist interventions to prevent error were reduced b

156 y readmission rate to the study institution, pharmacist interventions to prevent error, drug-drug int

157 3116 (39%) of 7934 pharmacist interventions were of an excessive duration.

158 Study personnel (except pharmacists), investigators, and patients were blinded t

159 sk for medication errors and that transplant pharmacist involvement leads to improved safety through

160 plant recipients and determine if transplant pharmacist involvement would improve safety.

161 ial interventions, and (ii) the education of pharmacists involving microbiologic topics.

162 We conclude that a clinical pharmacist is an important and cost-effective member of

163 A community-based nurse-pharmacist led pain clinic in the north of England.

164 on, pharmacist-driven patient education, and pharmacist-led adverse event and adherence monitoring.

165 tise can achieve substantial returns through pharmacist-led antimicrobial stewardship programmes and

166 mprehensive hospital-based ASP that included pharmacist-led audit and feedback on institutional AMR.

167 mprehensive hospital-based ASP that included pharmacist-led audit-and-feedback on institutional AMR.

168 Pharmacist-led care increased the number or dose of medi

169 Data Synthesis: Pharmacist-led care was associated with similar numbers

170 To determine the effectiveness and harms of pharmacist-led chronic disease management for community-

171 tates and of any design reported outcomes of pharmacist-led chronic disease management versus a compa

172 Conclusion: Pharmacist-led chronic disease management was associated

173 A pharmacist-led comprehensive medication assessment demon

174 nd medical record extraction compared with a pharmacist-led comprehensive medication assessment.

175 ultivariable adjustment, association between pharmacist-led education and dabigatran adherence was no

176 patient selection was performed at 31 sites, pharmacist-led education was provided at 30 sites, and p

177 V care through off-hours facility access and pharmacist-led group drug distribution.

178 feedback for at-risk patients (control) or a pharmacist-led information technology intervention (PINC

179 tensification of Medications intervention, a pharmacist-led intervention combining elements found in

180 County barbershops were assigned to either a pharmacist-led intervention or an active control group.

181 ntervention comprises 4 main components: (1) pharmacist-led medication reconciliation and tailoring;

182 , 1.14; 95% CI, 1.05-1.25), and provision of pharmacist-led monitoring (RR, 1.25; 95% CI, 1.11-1.41)

183 -led education was provided at 30 sites, and pharmacist-led monitoring at 28 sites.

184 a community hospital emergency department, a pharmacist-led penicillin allergy assessment via medical

185 We evaluated the impact of the pharmacist-led Safety Medication dASHboard (SMASH) inter

186 To determine whether a pharmacist-led, Heart360-enabled, home blood pressure mo

187 A pharmacist-led, Heart360-supported, home BP monitoring i

188 We tested whether a pharmacist-led, information technology-based interventio

189 t, and formally review interventions made by pharmacists, locum arrangements, and the workload of jun

190 The pharmacist made 366 recommendations related to drug orde

191 Nurse and pharmacist managed community-based pain clinics can effe

192 practitioners and physician assistants, and pharmacist members of four national critical care societ

193 8 countries among experts including hospital pharmacists, microbiologists, and infectious disease spe

194 laboratory staff were masked, but the study pharmacist (MK), vaccine administrator, and study statis

195 ce to the active drug; the study physicians, pharmacists, monitors, and patients remained masked duri

196 Compared to ICUs with clinical pharmacists, mortality rates in ICUs that did not have c

197 rviews were conducted with doctors (n = 10), pharmacists (n = 10), and nurses and midwives (n = 19) i

198 , respiratory therapists (n = 31, 0.4%), and pharmacists (n = 30, 0.4%).

199 Physicians and compounding pharmacists need to be aware that international counterf

200 ntervention included: real-time MALDI-TOF MS pharmacist notification and prospective AMS provider fee

201 dres of health-care professionals, including pharmacists, nurses, and community health workers, to me

202 sults immediately to the pharmacy and alerts pharmacists of potential interventions, and (ii) the edu

203 negatively associated with the presence of a pharmacist on-site (odds ratio 0.66 [0.56-0.78], p<0.000

204 intervention by infectious disease clinical pharmacists on the basis of the results of tests for mec

205 Patients, trial investigators and staff, pharmacists or dispensers, laboratory staff (with the ex

206 her and when, during their interactions with pharmacists or salespeople, the discounts specified in S

207 At randomisation, site pharmacists (or delegates) received a randomisation numb

208 systematic medication titration by doctors, pharmacists, or patients; education; or lifestyle counse

209 r patient outcomes are enhanced by effective pharmacist-patient interactions.

210 ocation was not masked to general practices, pharmacists, patients, or researchers who visited practi

211 Pharmacists performed medication reconciliation in 17 of

212 ounds that included a respiratory therapist, pharmacist, physician and nurse; and protocol use as hav

213 A growing number of pharmacists practice in critical care.

214 A research pharmacist prepared the randomisation code using a compu

215 Pharmacists prepared the syringes.

216 Pharmacists prescribed medications and ordered laborator

217 ents pertaining to the TIRF REMS, surveys of pharmacists, prescribers, and patients reflected general

218 (1) Knowledge assessments of pharmacists, prescribers, and patients; (2) survey and c

219 Pharmacist prescribing for patients with hypertension re

220 We aimed to study the impact of pharmacist prescribing on blood pressure (BP) control in

221 n = 64, mean rate 3.0 per patient); however, pharmacists prevented 119 of these errors (1.9 errors pe

222 A pharmacist provided a 9-month multilevel intervention, w

223 We hypothesised that pharmacist provision of the progestogen-only pill as a b

224 critical care physician, nurse practitioner, pharmacist, psychologist, and case manager.

225 lthcare professionals (e.g. doctors, nurses, pharmacists, radiographers etc.) and others involved in

226 avings (or loss) that resulted from clinical pharmacist recommendations.

227 Pharmacists recorded all recommendations, which were the

228 k, were reviewed, with 7934 interventions by pharmacists recorded for the five targeted measures, sug

229 Pharmacists representing 347 of 431 eligible pharmacies

230 Between October 2014 and June 2015, a pharmacist researcher directly observed solid, orally ad

231 asked to treatment assignment apart from the pharmacist responsible for preparing the study treatment

232 Pharmacist review of medication orders in the intensive

233 Pharmacists reviewed medication histories.

234 actionable, patient-level feedback; and (3) pharmacists reviewing individual at-risk patients, and i

235 vides background information on the clinical pharmacist's role, training, certification, and potentia

236 usion, we have found evidence that community pharmacists, school first aiders and primary care nurses

237 Pharmacists' scope of practice is evolving, and their po

238 Physicians and pharmacists should be educated in how to provide access

239 ce, patients received standardized HIV nurse/pharmacist support, which included nurse visits and tele

240 was sourced from a panel survey of hospital pharmacists, surgeons, and theatre nurses who are involv

241 % to -0.53%, I2 91.0%, n = 13, p < 0.001) in pharmacist task-sharing studies, and -0.27% (-0.50% to -

242 ded telephone nurse care managers, telephone pharmacists, telepsychologists, and telepsychiatrists.

243 ceutical care were more satisfied with their pharmacist than the usual care group (P =.03) and the PE

244 ped by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America,

245 CCSC members, including physicians, nurses, pharmacists, therapists, and others.

246 pment, supplies and personnel, and dedicated pharmacist time for blood culture review and of making i

247 r an initial telephone visit with a nurse or pharmacist to guide follow-up or an initial in-person cl

248 ment packs with sequential allocation by the pharmacist to receive 56 days of treatment with standard

249 atient ratio, and the addition of a clinical pharmacist to the multidisciplinary team.

250 utions may enhance the preparation of future pharmacists to contribute to effective antimicrobial ste

251 efforts to overcome these barriers, allowing pharmacists to deliver high-quality patient care to the

252 SMASH comprised (1) training of clinical pharmacists to deliver the intervention; (2) a web-based

253 Payers should refrain from forcing pharmacists to dispense generic drugs in patients on mai

254 d 1998, of educational outreach by community pharmacists to influence physician prescribing in Englan

255 hthalmologists should work with insurers and pharmacists to prevent such discontinuation of use as ge

256 ed that a formal, consistent intervention by pharmacists to promote adherence to our institution's se

257 he feasibility of GP practice-based clinical pharmacists to screen the over-65s for AF, using digital

258 Existing regulations prohibiting pharmacists to sell antibiotics over-the-counter must be

259 The pharmacists' training in pharmacology, pharmacokinetics,

260 e sustained safely for 1 year while reducing pharmacist travel time.

261 The pharmacist, treating physician, and coordinator at each

262 Participants, clinicians, pharmacists, trial nurses, and midwives were masked to s

263 A research pharmacist unblinded to treatment strategy managed dose

264 stewardship program (ASP) physicians and/or pharmacists used a standardized survey to collect data o

265 Furthermore, diagnosis of AF by the clinical pharmacist using an SLECG was more sensitive and more sp

266 ts were randomly assigned (1:1) by the trial pharmacist, using previously generated treatment allocat

267 Pharmacists utilized the scoring tool and the institutio

268 iety, and the Society of Infectious Diseases Pharmacists vancomycin consensus guidelines committee.

269 cipation in these programs by physicians and pharmacists varies by state, and funding for continuatio

270 xt allocation was obtained by the study site pharmacist via an interactive voice-response system.

271 intervention continued with fewer in-person pharmacist visits to test whether the intervention effec

272 An infectious disease and/or critical care pharmacist was contacted with the microarray assay resul

273 fection studied, the involvement of clinical pharmacists was evaluated in 8,927-54,042 patients from

274 AF screening performed by GP practice-based pharmacists was feasible, economically viable, and posit

275 suggest that team-based care using clinical pharmacists was implemented in diverse primary care offi

276 and all study staff other than the research pharmacist were masked to medication assignment.

277 During the intervention period, pharmacists were alerted to patients with SAB via a pati

278 ity rates in ICUs that did not have clinical pharmacists were higher by 23.6% (p < 0.001, 386 extra d

279 ll patients, investigators, study staff, and pharmacists were masked to treatment allocation.

280 site study staff with the exception of site pharmacists were masked to treatment assignment.

281 Pharmacists were trained by a cardiologist to pulse palp

282 Only 234 patients (evaluated by pharmacists) were included in the final analysis.

283 ants who received treatment and the research pharmacist who implemented the randomisation and provide

284 to the treatment assignment, except for the pharmacist who prepared the ISIS-APO(a)Rx or placebo.

285 to treatment assignment, except for the site pharmacist who prepared the study drug but had no intera

286 ed using a web-based application by the site pharmacist who then masked the solution for infusion.

287 e BP telemonitors and transmitted BP data to pharmacists who adjusted antihypertensive therapy accord

288 Cross-tabulation showed that pharmacists who are aware of the guidelines of atopic de

289 ntion group, barbers promoted follow-up with pharmacists who prescribed BP medication under a collabo

290 Participants were recruited by their pharmacist, who enrolled adults at high risk for CVD.

291 ted a survey of the instructions provided by pharmacists, who play an important role in educating pat

292 The pharmacist will work with the patient and collaborate wi

293 ealth professionals that includes a clinical pharmacist with expertise in optimal and comprehensive m

294 Engagement of community pharmacists with an expanded scope of practice could hav

295 ed HIV Care Model integrated community-based pharmacists with HIV medical providers and required them

296 armaceutical care program (n = 447) provided pharmacists with recent patient-specific clinical data (

297 Pharmacists, with the aid of the patient-reported inform

298 Recent increases in the number of clinical pharmacists within primary care makes them ideally place

299 Local pharmacists without residency or prior antimicrobial ste

300 m within the long-term care facility and the pharmacists' work activity system outside the facility.